Skip to main content
Signal8

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

$REGNPress releaseNov 12, 2026, 5:00 PM ETRead the release

Regeneron announced positive Phase 2 PINNACLE trial results for baloncibart, a first-in-class NPR1-blocking antibody, in postural orthostatic tachycardia syndrome (POTS), a condition with no FDA-approved treatments. A single 450 mg dose reduced the standing heart-rate response versus placebo by an LS mean difference of -11.4 bpm at day 8 (nominal p=0.0007) and -7.4 bpm at day 29, and improved orthostatic symptoms and physical functioning on the LWPQ questionnaire. The 150 mg dose showed a day-8 effect that was not maintained at day 29.

Key figures

Drug Name
baloncibart (REGN7544)
Phase Of Trial
Phase 2
Trial enrollment
82
Us pots prevalence
500,000 to several million
Planned phase3 timing
first half of 2027
Primary endpoint p value
0.0007
Day29 ls mean difference bpm
-7.4
Primary endpoint ls mean difference bpm
-11.4

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.